Edwards Lifesciences Comments on TAVR National Coverage Decision

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, pro.

Business Wire • Sep 10, 2026

Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Sep 7, 2026

Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl.

Business Wire • Sep 2, 2026

Should You Hold Edwards Lifesciences Stock in Your Portfolio?

EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.

Zacks Investment Research • Aug 20, 2026

Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.

Zacks Investment Research • Aug 14, 2026

Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation

Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.

Zacks Investment Research • Aug 13, 2026

Aristotle Value Equity WM Q2 2026 Portfolio Performance

For the second quarter of 2026, Aristotle Capital's Value Equity WM Composite posted a total return of 4.36% pure gross of fees (3.85% net of fees). Corteva, the seed and crop protection company, was one of the largest detractors during the period. Motorola Solutions, the provider of mission-critical communications and security systems, was one of the largest detractors during the quarter.

Seeking Alpha • Aug 6, 2026

Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?

Investors need to pay close attention to EW stock based on the movements in the options market lately.

Zacks Investment Research • Jul 30, 2026

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

Edwards Lifesciences Corp. (NYSE:EW) stock rose Friday after the medical device maker reported second-quarter results that topped Wall Street estimates and raised the low end of its full-year revenue guidance.

Benzinga • Jul 24, 2026

Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises

EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.

Zacks Investment Research • Jul 24, 2026